Want to see JP:7741 full AI Analyst Report?
Top Page
HOYA
(7741)
Select Model
Select Model
Rating:71Outperform
Price Target:
¥27,266.00
▲(10.28% Upside)
Action:Reiterated
Date:08/01/26
Strong financial performance is the primary positive (exceptional profitability, conservative balance sheet, and solid cash generation), but the overall score is held back by weak technical positioning (trading below major moving averages) and a relatively expensive valuation (P/E 33.13 with a modest ~1.20% yield).
Positive Factors
High profitability
Sustained very high gross and operating margins reflect durable pricing power from proprietary materials and precision manufacturing. These margins support robust cash generation, fund R&D/capex and provide resilience against cyclical revenue swings, underpinning long-term returns.
Negative Factors
Moderating revenue growth
Top-line momentum has slowed from prior stronger years, which risks pressuring future margin expansion and makes sustaining high ROE harder without new product or geographic growth. If growth stays muted, capital returns or reinvestment must be balanced against higher profitability expectations.
Read all positive and negative factors
Positive Factors
Negative Factors
High profitability
Sustained very high gross and operating margins reflect durable pricing power from proprietary materials and precision manufacturing. These margins support robust cash generation, fund R&D/capex and provide resilience against cyclical revenue swings, underpinning long-term returns.
Read all positive factors
HOYA (7741) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥8.24T
Dividend Yield1.2%
Average Volume (3M)1.07M
Price to Earnings (P/E)31.2
Beta (1Y)0.80
Revenue Growth12.65%
EPS Growth32.11%
CountryJP
Employees37,752
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)790.16
Shares Outstanding334,838,000
10 Day Avg. Volume1,057,600
30 Day Avg. Volume1,072,613
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)8.85
Price to Sales (P/S)9.53
P/FCF Ratio40.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥31,275.00Price Target Upside26.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)805.26
Revenue Forecast (FY)¥1.03T
HOYA Business Overview & Revenue Model
Company Description
Globally recognized as a med-tech innovator, HOYA Corporation is a prominent provider of advanced technology and healthcare solutions worldwide. Its comprehensive portfolio of life care products encompasses vision correction items such as eyeglass...
How the Company Makes Money
HOYA makes money primarily by manufacturing and selling specialized, high-margin optical and precision products across several major revenue streams:
1) Vision care (eyeglass lenses and related products)
- Product sales: A large portion of HOYA’s...
HOYA Financial Statement Overview
Summary
Income Statement
92
Very Positive
Balance Sheet
95
Very Positive
Cash Flow
88
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 983.09B | 947.75B | 866.03B | 762.61B | 723.58B | 661.47B |
| Gross Profit | 775.65B | 748.64B | 693.58B | 606.30B | 567.05B | 511.05B |
| EBITDA | 405.25B | 387.88B | 309.48B | 284.45B | 266.20B | 254.48B |
| Net Income | 267.04B | 253.08B | 202.10B | 181.38B | 168.64B | 164.51B |
Balance Sheet | ||||||
| Total Assets | 1.30T | 1.30T | 1.23T | 1.20T | 1.03T | 992.84B |
| Cash, Cash Equivalents and Short-Term Investments | 555.49B | 574.09B | 533.97B | 525.16B | 405.89B | 419.40B |
| Total Debt | 45.39B | 42.24B | 37.28B | 29.24B | 24.58B | 21.60B |
| Total Liabilities | 271.23B | 265.89B | 262.65B | 241.36B | 213.72B | 203.78B |
| Stockholders Equity | 1.02T | 1.02T | 974.02B | 967.76B | 818.32B | 803.85B |
Cash Flow | ||||||
| Free Cash Flow | 236.11B | 221.87B | 187.19B | 181.73B | 168.36B | 161.18B |
| Operating Cash Flow | 290.47B | 278.45B | 235.11B | 222.80B | 201.83B | 190.06B |
| Investing Cash Flow | -2.35B | -7.59B | -35.82B | -35.81B | -39.93B | -29.13B |
| Financing Cash Flow | -310.40B | -261.26B | -187.72B | -110.89B | -202.16B | -106.89B |
HOYA Technical Analysis
Positive
24725.00
Price Trends
25797.60
Positive
26874.23
Negative
25841.60
Positive
Market Momentum
-187.61
Negative
56.36
Neutral
85.64
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7741, the sentiment is Positive. The current price of 24725 is below the 20-day moving average (MA) of 24899.00, below the 50-day MA of 25797.60, and below the 200-day MA of 25841.60, indicating a bullish trend. The MACD of -187.61 indicates Negative momentum. The RSI at 56.36 is Neutral, neither overbought nor oversold. The STOCH value of 85.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7741.
HOYA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥953.31B | 31.30 | 19.68% | 1.36% | 15.13% | 196.11% | |
71 Outperform | ¥8.24T | 31.23 | 25.12% | 1.19% | 12.65% | 32.11% | |
71 Outperform | ¥3.43T | 25.23 | 9.19% | 1.39% | 9.24% | 16.68% | |
67 Neutral | ¥148.91B | 17.97 | 24.90% | 1.53% | 15.46% | 6.44% | |
66 Neutral | ¥2.00T | 29.66 | 8.94% | 1.65% | 1.34% | -40.41% | |
54 Neutral | ¥132.02B | 21.87 | 6.57% | 1.78% | 3.39% | 6.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7741
HOYA
25,900.00
7,426.34
40.20%
JP:4543
Terumo
2,288.00
-239.39
-9.47%
JP:7747
Asahi Intecc Co
3,638.00
1,272.15
53.77%
JP:3046
JINS HOLDINGS
6,500.00
-1,232.50
-15.94%
JP:7780
Menicon Co
1,757.00
567.00
47.65%
JP:7733
Olympus
1,807.00
30.53
1.72%
HOYA Corporate Events
HOYA Ties Executive Pay to Long-Term Performance With New Treasury Stock Grants
Jul 31, 2026
HOYA Corporation is a Japan-based manufacturer in the optical and electronics fields, best known for eyeglass lenses, optical glass, medical endoscopes and semiconductor-related products. Listed on the Tokyo Stock Exchange Prime Market under code ...
HOYA Delivers Strong Q1 Earnings and Projects Robust First-Half Growth
Jul 31, 2026
HOYA Corporation reported strong growth for the three months ended June 30, 2026, with revenue rising 16.0% year on year to ¥255.7 billion and profit for the quarter climbing 28.1% to ¥65.8 billion. Profit margins improved across operati...
HOYA Launches Strategic Review of Global PENTAX Medical Endoscope Business
Jul 31, 2026
HOYA Corporation has launched a strategic review of its global PENTAX Medical endoscope business, covering operations in Japan and overseas as part of its ongoing portfolio optimization. The move follows the planned transfer of Japan-based endosco...
Hoya Launches ¥200 Billion Share Buyback to Boost Capital Efficiency
Jul 31, 2026
Hoya Corporation’s board has approved a new share repurchase program targeting up to 10 million common shares, representing about 2.99% of its outstanding stock, for a maximum outlay of 200 billion yen. The buyback will run from August 3, 20...
Hoya Extends Restricted Stock Unit Plan to Strengthen Executive Incentives
Jun 26, 2026
Hoya Corporation will continue its Restricted Stock Units compensation plan for executive officers, first introduced in fiscal 2025 as a mid- to long-term incentive scheme. The plan is designed to align executives’ interests with shareholder...
Hoya Extends Performance-Based Share Plan Tied to Financial and ESG Targets
Jun 26, 2026
Hoya Corporation will continue its performance-based stock compensation plan for executive officers, first introduced in fiscal 2019, as a mid- to long-term incentive aligning leadership rewards with corporate performance. The plan grants shares b...
HOYA Nearly Doubles Annual Dividend, Emphasizes Progressive Payout Policy
May 28, 2026
HOYA Corporation’s board has approved a year-end dividend of 170 yen per share for the fiscal year ended March 31, 2026, payable on June 5 to shareholders of record as of March 31. Combined with the interim dividend of 125 yen already paid, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.